Work

Clinician perspectives on infusion site‐of‐care shifts in pediatric inflammatory bowel disease: An anonymous national web‐based survey

Year: 2026

Type: article

Abstract: Commercial payers and pharmacy benefit managers use site-of-care and specialty drug distribution policies (including white bagging and brown bagging) that can redirect infusion-based biologic therapies from hospital outpatient departments to alternate settings. We conducted an anonymous web-based survey distributed via a national pediatric gastroenterology (GI) listserv (February 13-27, 2026) to characterize perceived access barriers and decision drivers for acceptable infusion sites among pediatric inflammatory bowel disease (IBD) clinicians. Among 100 respondents, prior authorization/payer friction was most frequently rated as a major/severe pain point (66%). The highest-rated decision drivers were reaction management capability (88% very/extremely important), reliable communication back to the GI team (88%), patient experience (88%), and pediatric infusion expertise (87%). These findings highlight administrative burden as the dominant barrier and underscore the importance of safety capability and bidirectional care integration when pediatric patients with IBD are shifted across sites of care.

Source: JPGN Reports

DOI: 10.1002/jpr3.70238

Author: Brad Pasternak

Institution: Phoenix Children's Hospital

Language: English

Topic: Inflammatory Bowel Disease

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,900